000060420 001__ 60420
000060420 005__ 20190709135527.0
000060420 0247_ $$2doi$$a10.1016/j.ctrv.2016.12.005
000060420 0248_ $$2sideral$$a97899
000060420 037__ $$aART-2017-97899
000060420 041__ $$aeng
000060420 100__ $$aPerez-Gracia, J.
000060420 245__ $$aStrategies to design clinical studies to identify predictive biomarkers in cancer research
000060420 260__ $$c2017
000060420 5060_ $$aAccess copy available to the general public$$fUnrestricted
000060420 5203_ $$aThe discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. This has led to the proliferation of a myriad of exploratory studies using dissimilar strategies, most of which fail to identify any promising targets and are seldom validated. The lack of a proper methodology also determines that many anti-cancer drugs are developed below their potential, due to failure to identify predictive biomarkers. While some drugs will be systematically administered to many patients who will not benefit from them, leading to unnecessary toxicities and costs, others will never reach registration due to our inability to identify the specific patient population in which they are active. Despite these drawbacks, a limited number of outstanding predictive biomarkers have been successfully identified and validated, and have changed the standard practice of oncology. In this manuscript, a multidisciplinary panel reviews how those key biomarkers were identified and, based on those experiences, proposes a methodological framework—the DESIGN guidelines—to standardize the clinical design of biomarker identification studies and to develop future research in this pivotal field.
000060420 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000060420 590__ $$a8.122$$b2017
000060420 591__ $$aONCOLOGY$$b21 / 222 = 0.095$$c2017$$dQ1$$eT1
000060420 592__ $$a3.42$$b2017
000060420 593__ $$aMedicine (miscellaneous)$$c2017$$dQ1
000060420 593__ $$aRadiology, Nuclear Medicine and Imaging$$c2017$$dQ1
000060420 593__ $$aOncology$$c2017$$dQ1
000060420 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000060420 700__ $$aSanmamed, M.F.
000060420 700__ $$aBosch, A.
000060420 700__ $$aPatiño-Garcia, A.
000060420 700__ $$aSchalper, K.A.
000060420 700__ $$aSegura, V.
000060420 700__ $$aBellmunt, J.
000060420 700__ $$aTabernero, J.
000060420 700__ $$aSweeney, C.J.
000060420 700__ $$aChoueiri, T.K.
000060420 700__ $$aMartín, M.
000060420 700__ $$aFusco, J.P.
000060420 700__ $$aRodriguez-Ruiz, M.
000060420 700__ $$aCalvo, A.
000060420 700__ $$aPrior, C.
000060420 700__ $$aPaz-Ares, L.
000060420 700__ $$aPio, R.
000060420 700__ $$aGonzalez-Billalabeitia, E.
000060420 700__ $$aGonzalez Hernandez, A.
000060420 700__ $$aPáez, D.
000060420 700__ $$aPiulats, J.M.
000060420 700__ $$aGurpide, A.
000060420 700__ $$aAndueza, M.
000060420 700__ $$ade Velasco, G.
000060420 700__ $$0(orcid)0000-0002-8026-7391$$aPazo, R.
000060420 700__ $$aGrande, E.
000060420 700__ $$aNicolas, P.
000060420 700__ $$aAbad-Santos, F.
000060420 700__ $$aGarcia-Donas, J.
000060420 700__ $$aCastellano, D.
000060420 700__ $$aPajares, M.J.
000060420 700__ $$aSuarez, C.
000060420 700__ $$aColomer, R.
000060420 700__ $$aMontuenga, L.M.
000060420 700__ $$aMelero, I.
000060420 773__ $$g53 (2017), 79-97$$pCancer treat. rev.$$tCANCER TREATMENT REVIEWS$$x0305-7372
000060420 8564_ $$s1639921$$uhttps://zaguan.unizar.es/record/60420/files/texto_completo.pdf$$yVersión publicada
000060420 8564_ $$s100527$$uhttps://zaguan.unizar.es/record/60420/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000060420 909CO $$ooai:zaguan.unizar.es:60420$$particulos$$pdriver
000060420 951__ $$a2019-07-09-12:00:06
000060420 980__ $$aARTICLE